The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Neoadjuvant dose-dense anthracycline and cyclophosphamide in combination with carboplatin, paclitaxel, and pembrolizumab for triple-negative breast cancer: A systematic review and meta-analysis.
 
Vitor Liutti
Honoraria - AstraZeneca/Daiichi Sankyo; Blanver; Bristol-Myers Squibb; Janssen; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Daiichi Sankyo; Novartis
Research Funding - AstraZeneca/UK (Inst); BeiGene (Inst); Daiichi Sankyo (Inst); HUYA Bioscience International (Inst); Incyte (Inst); Janssen (Inst); Lilly (Inst); MSD (Inst); Novartis (Inst); Roche (Inst); Seagen (Inst); Tolmar (Inst)
Travel, Accommodations, Expenses - Adium Pharma; MSD
 
David Vale
No Relationships to Disclose
 
Bruno Lins de Souza
No Relationships to Disclose
 
Mariana Fauth Seibel
No Relationships to Disclose
 
Rafael Manea
Honoraria - Bayer
 
Daniel Araujo
Honoraria - AstraZeneca; Libbs; MSD; Novartis; Tersera
Consulting or Advisory Role - MSD Oncology